http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Chong-jen Yu ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Mok, Tony S.K.,Wu, Yi-Long,Yu, Chong-Jen,Zhou, Caicun,Chen, Yuh-Min,Zhang, Li,Ignacio, Jorge,Liao, Meilin,Srimuninnimit, Vichien,Boyer, Michael J.,Chua-Tan, Marina,Sriuranpong, Virote,Sudoyo, Aru W.,J American Society of Clinical Oncology 2009 Journal of clinical oncology Vol.27 No.30
<B>Purpose</B><P>This study investigated whether sequential administration of erlotinib and chemotherapy improves clinical outcomes versus chemotherapy alone in unselected, chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC).</P><B>Patients and Methods</B><P>Previously untreated patients (n = 154) with stage IIIB or IV NSCLC and Eastern Cooperative Oncology Group performance status of 0 or 1 were randomly assigned to receive erlotinib (150 mg/d) or placebo on days 15 to 28 of a 4-week cycle that included gemcitabine (1,250 mg/m<SUP>2</SUP>days 1 and 8) and either cisplatin (75 mg/m<SUP>2</SUP>day 1) or carboplatin (5 × area under the serum concentration-time curve, day 1). The primary end point was nonprogression rate (NPR) at 8 weeks. Secondary end points included tumor response rate, NPR at 16 weeks, duration of response, progression-free survival (PFS), overall survival (OS), and safety.</P><B>Results</B><P>The NPR at 8 weeks was 80.3% in the gemcitabine plus cisplatin or carboplatin (GC) -erlotinib arm (n = 76) and 76.9% in the GC-placebo arm (n = 78). At 16 weeks, the NPR was 64.5% for GC-erlotinib versus 53.8% for GC-placebo. The response rate was 35.5% for GC-erlotinib versus 24.4% for GC-placebo. PFS was significantly longer with GC-erlotinib than with GC-placebo (adjusted hazard ratio, 0.47; log-rank P = .0002; median, 29.4 v 23.4 weeks); this benefit was consistent across all clinical subgroups. There was no significant difference in OS. The addition of erlotinib to chemotherapy was well tolerated, with no increase in hematologic toxicity, and no treatment-related interstitial lung disease.</P><B>Conclusion</B><P>Sequential administration of erlotinib following gemcitabine/platinum chemotherapy led to a significant improvement in PFS. This treatment approach warrants further investigation in a phase III study.</P>
-
( Chin-chung Shu ),( Meng-kun Tsai ),( Shu-wei Lin ),( Chih-yuan Lee ),( Jann-yuan Wang ),( Chong-jen Yu ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: The prevalence and incidence of latent tuberculosis infection (LTBI) in patients with kidney transplant remains unclear. Methods: In this prospective study, we enrolled kidney transplant candidates (KTCs) and recipients (KTRs) from 2014 to 2018. We defined LTBI as a positive result of QuantiFERON-TB Gold In-tube (QFT). We analyzed the predictors for LTBI acquisition and followed QFT test for 2 years among those initially without LTBI. Results: Of 425 patients enrolled, 305 (71.8%) patients belonged to the KTC group and 120 (28.2%) to the KTR group. The initial QFT showed positive results in 33 (10.8%) and 25 (20.8%) in the KTC and KTR groups, respectively (p=0.007). The QFT response value in LTBI patients was higher in the KTR group than in the KTC group (1.85 vs. 1.06 IU/ml, p=0.046). Multivariate logistic regression showed that old age, absence of Bacillus Calmette-Guerin scar, and KTR group were independent factors for positive LTBI. For participants with initial negative QFT, positive QFT conversion within 2-year follow-up was higher after kidney transplantation (20%) than in KTCs (5.5%) (p=0.032). Conclusion: This study is the first cohort to follow up LTBI status in patients with kidney transplant and shows its higher prevalence and incidence in those belong to KTR. It indicates that surveillance of LTBI after renal transplantation is important.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
